FDA's Fast-Track for Rexulti Raises Concerns

CMS efforts to reduce use of unnecessary antipsychotics in nursing homes may conflict with marketing efforts for the drug.

FDA's Fast Track Approval Coronavirus Treatment Acceleration Program

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for Agitation - Mad In America

FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for Recurrent Glioblastoma

Listen to New FDA Approvals podcast

The Science Of A Biotech Valuation: How To Interpret The Value Of FDA Expedited Programs (NASDAQ:IBB)

FDA fast-tracks drug for dementia agitation that increases risk of death 4 times - Study Finds

Amgen Triumphs in $27.8 Billion Horizon Buyout Battle

Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular Dystrophy

FDA fast-tracks drug for dementia agitation that increases risk of death 4 times - Study Finds